Informing iQOS Regulations in the United States: A Synthesis of What We Know
Dados Bibliográficos
| AUTOR(ES) | |
|---|---|
| AFILIAÇÃO(ÕES) | The Hebrew University of Jerusalem, Israel, The George Washington University, Washington, DC, USA |
| ANO | 2020 |
| TIPO | Artigo |
| PERIÓDICO | SAGE Open |
| ISSN | 2158-2440 |
| E-ISSN | 2158-2440 |
| DOI | 10.1177/2158244019898823 |
| ADICIONADO EM | 2025-08-18 |
| MD5 |
c6388a81ab1ed588676d1eb144d8f671
|
Resumo
The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International's (PMI) 'iQOS' has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Administration announced permission for PMI to sell iQOS in the United States in April 2019, and iQOS was launched in October 2019. Decisions pending its modified risk tobacco product (MRTP) application will occur subsequently. The U.S. regulatory efforts regarding iQOS could be informed by examining (a) Philip Morris USA other product marketing efforts and (b) the iQOS market in countries where it is available. This article briefly addresses these two points with extant literature and suggests that future research should address important gaps in what is currently known, including strategic international collaborations and research, which historically has been critical for advancing tobacco control globally.